Targeting Complement Component 1q Ameliorates Diabetic Endothelial Inflammation Via Orphan Nuclear Receptor 4a1–Dependent Suppression of Nuclear Factor κB Signaling
Journal of the American Heart Association · 21.04.2026 · 15 (8)
DOI: 10.1161/jaha.125.044979 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 21.04.2026. Verfasst von Aiqin Mao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Wuxi School of Medicine Jiangnan University Wuxi China. Hauptthemen laut MEDLINE: NF-kappa B, Diabetes Mellitus, Experimental, Diabetic Angiopathies, Nuclear Receptor Subfamily 4, Group A, Member 1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Vascular inflammation triggers endothelial dysfunction, a pivotal factor in the pathogenesis of diabetic vascular complications. Complement component 1q (C1q), a crucial component of the immune system, is implicated in inflammation and immune responses. However, its role in modulating endothelial function in diabetes remains poorly understood. In this study, we aimed to investigate how C1q influences endothelial inflammation in diabetes and the underlying signaling mechanisms involved.
Methods
Gene expression in the aortas of streptozotocin‐induced mice or primary endothelial cells was detected using real‐time quantitative polymerase chain reaction, western blot, and immunofluorescence staining. Molecular docking identified dl ‐citrulline as a target for C1qa. Dihydroethidium staining was used to assess vascular reactive oxygen species generation, while Evans blue staining was used to evaluate vascular permeability.
Results
Here, we demonstrated that the upregulation of C1q in the aortic endothelial cells significantly reduces the expression of Nr4a1 (orphan nuclear receptor 4a1) and activates the nuclear factor κB signaling pathway, leading to vascular damage. Increasing Nr4a1 expression can mitigate C1q‐induced vascular injury. Additionally, the small molecule dl ‐citrulline downregulates C1q expression and alleviates endothelial inflammation in diabetes. Overexpression of Hoxa3 (homeobox a3), an upstream negative regulator of C1q transcription, protects against diabetic vascular injury.
Conclusions
Together, these findings highlight that C1q downregulation ameliorates endothelial inflammation in diabetes, providing mechanistic insights for developing therapeutic strategies against diabetic vascular complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wuxi School of Medicine Jiangnan University Wuxi China.
- School of Food Science and Technology Jiangnan University Wuxi China.
Zitieren
APA
Mao, A., Shi, X., Li, Z., Zhang, K., Kan, H., Geng, L., Zhou, T., & He, D. (2026). Targeting Complement Component 1q Ameliorates Diabetic Endothelial Inflammation Via Orphan Nuclear Receptor 4a1–Dependent Suppression of Nuclear Factor κB Signaling. Journal of the American Heart Association, 15(8). https://doi.org/10.1161/jaha.125.044979
Vancouver
Mao A, Shi X, Li Z, Zhang K, Kan H, Geng L, et al. Targeting Complement Component 1q Ameliorates Diabetic Endothelial Inflammation Via Orphan Nuclear Receptor 4a1–Dependent Suppression of Nuclear Factor κB Signaling. Journal of the American Heart Association. 2026;15(8). doi:10.1161/jaha.125.044979
BibTeX
@article{Mao2026,
author = {Mao, Aiqin and Shi, Xiaoming and Li, Zicheng and Zhang, Ka and Kan, Hao and Geng, Li and Zhou, Tingting and He, Dongxu},
title = {Targeting Complement Component 1q Ameliorates Diabetic Endothelial Inflammation Via Orphan Nuclear Receptor 4a1–Dependent Suppression of Nuclear Factor κB Signaling},
journal = {Journal of the American Heart Association},
year = {2026},
volume = {15},
number = {8},
doi = {10.1161/jaha.125.044979}
}
EUVIMED